Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma.
Yang LiuChunmeng WangXiang LiLiang DongQingming YangMeixia ChenFengxia ShiMalcolm BrockMiao LiuQian MeiJiejie LiuJing NieWeidong HanPublished in: Journal for immunotherapy of cancer (2021)
NCT02961101 and NCT03250962.